BTG2 suppresses cancer cell migration through inhibition of Src-FAK signaling by downregulation of reactive oxygen species generation in mitochondria

Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib

(2011) F Takahashi et al.   ONCOGENE

BTG2 is an LXXLL-dependent co-repressor for androgen receptor transcriptional activity

(2010) Xu-Dong Hu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Src redox regulation: Again in the front line

(2010) Elisa Giannoni et al.   FREE RADICAL BIOLOGY AND MEDICINE

Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion

(2009) X N Meng et al.   BRITISH JOURNAL OF CANCER

Structural Basis for the Antiproliferative Activity of the Tob-hCaf1 Complex

(2009) Masataka Horiuchi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer

(2008) M. Schmidt et al.   CANCER RESEARCH

The BTG2 protein is a general activator of mRNA deadenylation

(2008) Fabienne Mauxion et al.   EMBO JOURNAL

N-acetyl-l-cysteine fosters inactivation and transfer to endolysosomes of c-Src

(2008) Ewa K. Krasnowska et al.   FREE RADICAL BIOLOGY AND MEDICINE

TIS21 negatively regulates hepatocarcinogenesis by disruption of cyclin B1-Forkhead box M1 regulation loop

(2008) Tae Jun Park et al.   HEPATOLOGY

Crystal structures of human BTG2 and mouse TIS21 involved in suppression of CAF1 deadenylase activity

(2008) X. Yang et al.   NUCLEIC ACIDS RESEARCH